Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma
Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced...
Astellas Pharma
Astellas Pharma Reports Strong Q3 Results with 17.3% Revenue Growth
Japan-based Astellas Pharma Inc. (TYO: 4503) has released its financial report for Q3 of its...
Fudan-Zhangjiang’s JAK1 Inhibitor FZJ-003 Gel Enters Phase I Trial for Atopic Dermatitis
China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349, SHA: 688505) announced that a Phase I...
Astellas’ Fezolinetant Hits Menopause Trial Goals in China, Eyes Global Launch
Japan’s Astellas Pharma Inc. (TYO: 4503) announced positive results from a Phase III trial of...
Astellas Pharma Posts 17% Q1 Sales Growth Driven by Xtandi and Padcev
Japan-based Astellas Pharma Inc. (TYO: 4503) reported a 17.1% year-on-year (YOY) increase in global sales...